GLIPR1L1

Across TCGA pan-cancer cohorts, GLIPR1L1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GLIPR1L1 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GLIPR1L1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GLIPR1L1 expression acts as an unfavorable survival marker.

LUAD, KIRC, and LUSC are the cancer types where GLIPR1L1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.158	0.835	<.001	36	view →
KIRC	OS	Median	All	0.057	0.881	<.001	12	view →
LUSC	OS	Median	All	0.172	0.762	.002	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
SARC	OS	Median	All	0.016	0.861	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	OS	Median	III,IV	0.228	0.684	.023	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GLIPR1L1–LUAD (OS)

Open the LUAD breakdown →